NPS deal

NPS received $6 million in signing and licensing payments and SmithKline's venture capital affiliate, S.R. One, made a $7 million equity investment.

NPS has developed small, orally active organic molecules that act on the calcium receptor of the parathyroid cell, which is primarily responsible for regulating the level of calcium. ...